Clinical trials: Rivaroxaban
Liver Cirrhosis
Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis
The aim of this study is to investigate the pharmacokinetic and pharmacodynamic parameters of rivaroxaban and apixaban in patients with compensated liver cirrhosis (Child-Pugh class A and B).
- Trial name
- NCT04874428
- Testing
- Rivaroxaban 10 mg Oral Tablet, Apixaban 2.5 mg Oral Tablet
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
- Trial name
- NCT03214172
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Anticoagulation
Accessibility to New Drugs Versus SOC in Sweden
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment.
- Trial name
- NCT03684395
- Testing
- DOACs: Rivaroxaban, Dabigatran, Apixaban, Standard of care (Warfarin)
- Where
- Sweden
- Volunteers
- 68,056 people
- Sponsor
- Bayer
Peripheral Artery Disease
A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
This is a study to learn more about French patients who have peripheral artery disease (PAD) and who have had a revascularization procedure.
- Trial name
- PADELTO (NCT04824729)
- Testing
- Lower limb revascularization
- Where
- France
- Volunteers
- 227,613 people
- Sponsor
- Bayer
Atrial Fibrillation, Coronary Artery Disease
Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study
The purpose of the study is to evaluate non-inferiority of oral anticoagulant (OAC) monotherapy to OAC plus single antiplatelet therapy (APT) in patients with atrial fibrillation (AF) and prior (>12 months) coronary stenting.
- Trial name
- OAC-ALONE (NCT01962545)
- Testing
- OAC alone
- Where
- Japan
- Volunteers
- 690 people
- Sponsor
- Satoshi Shizuta
Atrial Fibrillation
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
Atrial Fibrillation (AF) affects 200,000 Canadians and increases risk of stroke, morbidity and mortality. Having a stroke can affect a patient's ability to speak, eat, walk, work, care for themselves, and interact with others.
- Trial name
- COBRRA-AF (NCT04642430)
- Testing
- Apixaban, Rivaroxaban
- Where
- 8 sites in Canada
- Volunteers
- 3,018 people
- Sponsor
- Ottawa Hospital Research Institute
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Hip Arthroplasty, Total, Prevention of Venous Thromboembolism
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Surgical hip replacement (total hip arthroplasty, THA) is associated with a high risk of venous thromboembolism, but the appropriate duration of postoperative medical thromboprophylaxis ("anticoagulation") remains highly…
- Trial name
- ENABLE-Hip (NCT06611319)
- Testing
- Prevention of Venous Thromboembolism
- Where
- 6 sites in Austria, Germany
- Volunteers
- 2,932 people
- Sponsor
- Prof. Stavros Konstantinides, MD
Atrial Fibrillation Patients With Intermediate Stroke Risk
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Atrial fibrillation (AF) increases the risk of stroke, and oral anticoagulation is strongly recommended for patients at high thromboembolic risk.
- Trial name
- NCT04437654
- Testing
- Anticoagulation group(DOAC group)
- Where
- South Korea
- Volunteers
- 1,803 people
- Sponsor
- Yonsei University
Atrial Fibrillation
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention…
- Trial name
- SAFARI (NCT01805531)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Bayer
Cerebral Venous Sinus Thrombosis
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to 20 mg rivaroxaban were…
- Trial name
- NCT06551402
- Testing
- Dabigatran Etexilate 150mg, Rivaroxaban 20 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Kafrelsheikh University
Patient With Anterior Myocardial Infarction
Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction
Despite the use of guideline directed optimal medical therapy, 12% of patients with stable coronary heart disease and 18% of patients with recent acute coronary syndrome experience recurrent major adverse cardiovascular events 1.
- Trial name
- NCT05744804
- Testing
- -group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg, (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Sohag University
Multiple Myeloma, Venous Thromboembolism (VTE)
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.
- Trial name
- NCT07907211
- Testing
- Aspirin, Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Lijuan
Ischemic Stroke
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
DO-IT is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (IVT) is safe and improves functional outcome in ischemic stroke patients with recent direct oral…
- Trial name
- DO-IT Cohort (NCT06556446)
- Testing
- Tenecteplase and Alteplase
- Where
- 33 sites in Austria, Belgium and 13 more
- Volunteers
- 2,800 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Subdural Hematoma, Atrial Fibrillation
Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma
Subdural hematoma (SDH) is a common disorder that typically results from head trauma and has increased in prevalence in recent decades.
- Trial name
- ATTAACH (NCT05472766)
- Testing
- Direct Acting Oral Anticoagulant starting at Day 30, Direct Acting Oral Anticoagulant starting at Day 90
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Sunnybrook Health Sciences Centre
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Stroke, Atrial Fibrillation
Efficacy and Safety of Oral Anticoagulants Among Thai Octogenarians With Nonvalvular Atrial Fibrillation
A retrospective cohort study of Thai octogenarians with nonvalvular atrial fibrillation (NVAF) initiating apixaban, dabigatran, rivaroxaban or warfarin was conducted in medical school hospital in Thailand.
- Trial name
- NCT04047654
- Testing
- Non vitamin K oral anticoagulants
- Where
- Thailand
- Volunteers
- 327 people
- Sponsor
- Mahidol University
Antiphospholipid Syndrome
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
The aim of this study was to observe the clinical efficacy and safety of rituximab (RTX) combination with telitacicept (TA) in patients of systemic lupus erythematosus secondary antiphospholipid syndrome (APS).
- Trial name
- NCT05644210
- Testing
- Telitacicept, Rituximab, Aspirin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Hospital of Shandong University
Symptomatic Superficial Vein Thrombosis
Rivaroxaban Anticoagulation for Superficial Vein Thrombosis
This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg Superficial Vein Thrombosis (> or = 5cm)…
- Trial name
- RASET (NCT02123524)
- Testing
- Rivaroxaban
- Where
- 11 sites in Canada
- Volunteers
- 85 people
- Sponsor
- McMaster University